🚨 $SLS just proved peptide vaccines can deliver real Phase 3 survival benefits. Now look at $GLSI.
Greenwich LifeSciences is running the exact same modality (HER2-targeted peptide vaccine GP2), but with a cleaner, larger Phase 3 design AND FDA Fast Track designation already in hand. 👇
Why $GLSI (FLAMINGO-01) stands out:
• Gold-Standard Design: Randomized, double-blind, placebo-controlled in pivotal arms (not open-label BAT)
• Massive Scale: 250-patient open-label arm already fully enrolled, scaling toward ~2,000 patients across ~180 sites—multiples larger than the 126-patient REGAL trial
• Huge Efficacy Cushion: Powered for HR 0.55 (interims at 28/56 events, final at 133), while Phase IIb & early Phase 3 open-label data point to a 70–80% recurrence reduction (HR ~0.2–0.3). If that holds, p-values could crush 0.035
• FDA Fast Track: Granted Sept 2025 for HLA-A*02 HER2+ breast cancer—unlocking rolling BLA review & faster approval
Peptide vaccines are officially having their moment. CEO Snehal Patel engineered $GLSI for maximum statistical confidence and speed to market.
$ONDS We did double bottom on the 4 hour chart.
1st the day chart. I have posted about thsi before. When a stock over time trades you have to zoom out. Nobody really knows where it is going. Here on the day chart you see the downward wicks ( blocked all out except raw chart). You see the reversals on the downward wicks back over time ( look 1/22- 05/22 ) then look at my crosshair at 08/25 or upward wick then reversal down ( later up).
These are major pivots. There is no on exact number when this happens but we that 4 hour double bottom on a 4 hour chart is significant. Is anything 100% never but the markets are kinda same mode, double bottoming.
Middle is 4 hour chart.
Right is Ortex and 1.5 million shares available now.
Bullish
$NIO needs to hire top forensic investigators ASAP—and trace the funding behind two major attacks:
1. Coordinated FUD: Who is paying the army of online bashers spreading fake negative stories across social media?
2. Algorithmic Shorting: Who is behind the relentless algo pressure and potential naked shorting capping the stock?
$NIO (and fellow Chinese stocks) have more than enough ammo to build a real case against market manipulators.
Time to shine a spotlight on the shorts. Staying long & bullish on $NIO!
$NBIS
The fact is had Bloom energy actually delivered power like they said they could on their own earnings call when DataOne started shutting down their illegal generators, Nebius would have actually crushed earnings not by the 8.4% they did, but by 38% and they still beat despite Bloom's failure to execute. That's how you should look at what occurred, things outside company control still couldn't stop them from beating earnings. Because of that 3rd party failure to execute, they will now recognize that revenue and ARR 2 months out instead, it didn't go anywhere. Now that revenue will instead juice another quarter when it's counted. Trading at 2.3x forward price to sales on a hyper growth globally scaling Ai hyperscaler? Had to buy more. Over 100% customer capex coverage, the capacity customers aren't paying for is being sold at 2x what customers are paying! Much ado about nothing.
$CBRS just dropped a MASSIVE catalyst combo—and Wall Street is finally waking up.
Cerebras Systems didn’t just beat Q3 earnings; it confirmed it’s becoming the #1 alternative to $NVDA for ultra-fast AI inference. 👇 The Latest News on $CBRS:
• Microsoft Deal Signed: $MSFT officially joins $AMZN and $ORCL as Cerebras' 3rd hyperscale cloud customer in just 6 months
• Q3 Earnings Beat: Core revenue jumped +70% YoY to $230.9M (Cloud revenue surged +272%) with a surprise adjusted profit of $0.12 EPS (vs -$0.14 est.)
• Massive Backlog: Sitting on $26.1 BILLION in remaining performance obligations (including its $20B OpenAI partnership)
• 2027 Explosion: Management raised FY26 guidance to $940M–$960M and expects revenue to TRIPLE in 2027
Trading around ~$101—still >40% below its $185 IPO price—while landing every major cloud giant on earth.
Are you sleeping on $CBRS? 🚀
🚨 Does $HUMA look like a company going bankrupt to you? Because the numbers say the exact opposite.
While bears scream "BK," look at what is actually happening under the hood:
+44% surge in hospital adoption (with high-margin recurring sales)
1st device already FDA-approved—setting up a massive de-risked path for Device #2 with incredible clinical data
50x to 100x bigger TAM: Entering the dialysis access market (where >50% of patients are hard-to-reach)
Just the pre-approval run-up into that dialysis catalyst alone could be massive.
At these levels, $HUMA doesn't look like a bankruptcy play—it looks like a prime buyout target for a medtech giant.
Bullish. 🚀
🚨 Pay close attention to the timing on $KEEL.
Companies don��t bring in a heavyweight Chief Legal Officer by accident—especially right in the middle of negotiating THREE major data center lease deals. 👀
Corey Banks just stepped in as CLO. In small-cap data center plays, legal hires at this exact stage usually mean one thing: contracts are moving to the final redline phase. ✍️
No more fluff. No more vague "AI roadmaps."
Wall Street only cares about ink on paper. If $KEEL gets these 3 leases signed, the re-rating could be massive.
Watching this one like a hawk. Follow for daily data center & AI infra setups. 📈🔥
$IBRX Two major points of many I enjoyed from yesterday’s conf call. Adcock stating top-line header numbers will be released at a medical conference ‘to ensure a greatest speaking slot’. BULLISH
Also IBRX to ask the FDA to let patients receive the drug with their first course of BCG.
With stellar top-line results, will the FDA approve that request? $$
“When Jefferies analyst Roger Song pressed Adcock on that point, Adcock said ImmunityBio was in talks to present the full results at a medical meeting. “The reason we have not provided the top-line head numbers yet is that we are working with medical congresses to present all of that, and if you give out in a press release, then they do not want to give you the great speaking slot on those.”
“At two London conferences, ImmunityBio (IBRX) CEO Richard Adcock put a new number behind Anktiva’s bladder cancer trial win and said the company plans to ask the FDA within weeks to let patients receive the drug with their first course of BCG.”
Bullish
🚨
$TE
IS MAKING A BIG BET ON THE AI OPTICS BOOM.
TE Connectivity just announced a $60M+ investment in a new 135,000 sq. ft. facility in Henrietta, New York.
Here's why it matters:
⚡ 800+ new jobs planned.
🏭 Production expected to begin in Spring 2027.
🔬 Focus on high-density Fiber Array Units (FAUs).
☁️ Targeting hyperscale AI data centers and cloud computing customers.
The bigger picture?
AI data centers need more than GPUs and electricity.
They need massive optical bandwidth, higher-density fiber connections, and lower-power connectivity.
$TE
is positioning itself right in the middle of that infrastructure buildout.
AI needs compute. Compute needs connectivity. And optical networking could be one of the biggest beneficiaries.
Keep
$TE
on your radar. 👀
$CAPR IMO: my take is cardiomyopathy is a huge contention with the heart drug in big pharma. Big pharma does not want a heart therapy from DMD to ever be beneficial more than statins, stints, bp meds, etc so the corrupt FDA held an Adcom to dismiss all claim to cardio therapy benefits.
The PUL upper level was not as contentious and not even discussed much at Adcom. FDA got CAPR to amend BLA but I remain hopeful it gets approved for at least PUL, some form of cardio expanded label use would be great.
$IREN $APLD $CIFR $NBIS The market is currently pricing these names based on everything that could go wrong, rather than what could go right. Eventually, sentiment will shift, and valuations will begin to reflect the enormous upside potential instead of the perceived risks.
Bullish
$AMZN'S ZOOX ROBOTAXIS ARE NOW AVAILABLE ON $UBER IN LAS VEGAS!
• First Zoox integration on Uber’s platform.
• Partnership with MGM Resorts.
• Los Angeles expansion planned for 2027.
$UBER is becoming the commercialization platform for the AV revolution.
$RIVN Huge buying volume will surge after Dec 9, and shorts are going to get wiped out. Rivian has been heavily shorted, so if they announce autonomous driving tech on 12/9 that beats market expectations, this thing is going to explode and trigger a massive short squeeze for the history books. I wouldn't be surprised if it hits $30 by EOY.
$IBRX
• ImmunityBio holds an exclusive global supply agreement with the Serum Institute of India, the world's largest vaccine manufacturer, to produce next-generation recombinant BCG (rBCG) and standard BCG. Because rBCG is still investigational in the U.S., ImmunityBio distributes it to American urologists and patients through an FDA-authorized Expanded Access Program (EAP) while pursuing a formal regulatory pathway.
• Japan BCG Laboratory (Tokyo-172 Strain). In May 2026, ImmunityBio signed an exclusive U.S. development and supply agreement with Japan BCG Laboratory (JBL), a Tokyo-based manufacturer that has produced BCG for over 70 years. The deal grants ImmunityBio exclusive U.S. rights to import and commercialize JBL's Tokyo-172 BCG strain, backed by positive Phase III trial data showing it is non-inferior to Merck's TICE BCG.
Bullish
$ONDS The media wants to blame Trump and Hegseth for the Iran drone strike. But Iran was already launching attacks across the region.
Drone sightings 4 hours earlier does not equal actionable warning of an imminent strike.
Where’s the proof commanders ignored a specific threat?
Just another rush to assign political blame, ignore facts, support the DSA / RINO narrative for impeachment. Political hack media dumbshits.
The reality is CUAS should have been shared with regional allies and deployed years earlier. If anything, the need is greater now since democrats will want to fund Iran and its Hamas/Houthi terrorist proxies.
Time to permanently turn the lights out on Iran’s mullahs and fund regional CUAS at all US military bases.
@SecretaryTurner Beautiful story told in this powerful video! Thank you Mr. Secretary for this meaningful series telling stories with important lessons.
@PastorMikeStone@BaptistLeaders Interesting that a church in Atlanta would say that removing a "gay-affirming church" could hinder church planting in the NW. I was the Exec. Director of the NWBC at the time and we would never have participated in starting such a church, nor did we have any such church.
Prestigious doctor leaves a crowded room stunned after asking pro-abortion politicians:
"If abortion is healthcare, my question is: what disease are you treating?"